← All trials
NCT03342807
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2017
- Primary completion
- Nov 30, 2019
- Completion date
- Nov 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Nanjing Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Cangzhou Center HospitalCollaborator
- Kunming Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Fujian Provincial HospitalCollaborator
- Jinhua Central HospitalCollaborator
- Shenzhen Baoan District People 's HospitalCollaborator
- Hebei UniversityCollaborator
- Wuxi Third People 's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.